Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHV-1400 in IgA Nephropathy
NCT07054684Phase 1Recruiting
- Sponsor
- Biohaven Ltd.
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of BHV-1400 in IgA nephropathy (IgAN), sponsored by Biohaven Ltd. Primary endpoints: Number of participants with Serious AEs (SAEs), AEs leading to discontinuation, deaths at 1 year and Number of participants with Grade 3-4 treatment-emergent laboratory abnormalities at 1 year. Started Jul 2025; status: recruiting.
02
Drugs
BHV-1400
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07054684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07054684.